,36,37 The PARAGON-HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction) trial only included patients with a known intolerance of renin-angiotensin system inhibitors, and renal function was not accounted for in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) analyses. The gene discussed is REN; the disease is hydrops fetalis.